Altimmune, Inc.ALTNASDAQ
Loading
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q4 2025 | 23.05% |
| Q3 2025 | -13.20% |
| Q2 2025 | 8.90% |
| Q1 2025 | -19.99% |
| Q4 2024 | -0.11% |
| Q3 2024 | -6.39% |
| Q2 2024 | -1.55% |
| Q1 2024 | 27.07% |
| Q4 2023 | -8.04% |
| Q3 2023 | 38.75% |
| Q2 2023 | -23.17% |
| Q1 2023 | -10.06% |
| Q4 2022 | -5.34% |
| Q3 2022 | 26.69% |
| Q2 2022 | 5.89% |
| Q1 2022 | -25.17% |
| Q4 2021 | -30.89% |
| Q3 2021 | 120.06% |
| Q2 2021 | 11.74% |
| Q1 2021 | 32.71% |
| Q4 2020 | -47.48% |
| Q3 2020 | 2.70% |
| Q2 2020 | 130.88% |
| Q1 2020 | 85.58% |
| Q4 2019 | -55.63% |
| Q3 2019 | 196.41% |
| Q2 2019 | -8.47% |
| Q1 2019 | 4.99% |
| Q4 2018 | -35.19% |
| Q3 2018 | -3.87% |
| Q2 2018 | -14.41% |
| Q1 2018 | 28.86% |
| Q4 2017 | -24.48% |
| Q3 2017 | 12.39% |
| Q2 2017 | 623.99% |
| Q1 2017 | -49.14% |
| Q4 2016 | 15.39% |
| Q3 2016 | 8.18% |
| Q2 2016 | 11.08% |
| Q1 2016 | -12.15% |